— Technology Description
Researchers in Prof. Jack Ladenson’s laboratory have discovered biomarkers and associated antibodies for Alzheimer’s disease (AD) that could be used for early/presymptomatic diagnosis or in clinical trials for AD drugs.
This patented technology is based on the i…
— Technology Description
This technology is patented bipolar sieve electrode designed to stimulate peripheral nerves in a specific direction and thereby expand the potential of using this type of neural interface device in clinical applications such as nerve regeneration and prosthetics.
Sieve elec…
— Background
Frontotemporal Dementia (FTD) is the second most common form of non-Alzheimer’s dementia in the population under 65 years old. FTD represents approximately 20% of all dementias and onset normally appears in the mid to late 50s. Clinically FTD is characterized by a progressive neur…
— Background: Alzheimer’s disease (AD) is the 6th leading cause of death in the United States, and yet causation of the disease is poorly understood and targets for therapeutic intervention are still being identified. Recently, mutations in the immune receptor TREM2 have been found to be strongl…
— Dr. Hiroko Yano and Dr. Albert Kim, and their research teams at the Washington University School of Medicine in St. Louis developed and extensively evaluated a novel therapeutic approach using DNMT inhibitors to treat Huntington’s Disease (HD) and other neurodegenerative disorders. Currently D…
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
